Doximity (DOCS) Earnings Date & Reports

Key Takeaways

• Doximity reported fiscal second quarter 2027 revenue of $174.5 million, up 3.6% year over year and ahead of the consensus estimate of roughly $171.1 million.
• Adjusted earnings per share (EPS) of $0.36 came in line with analyst expectations of about $0.35.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $88.9 million, a 50.9% margin, but GAAP operating margin narrowed to 25.2% from 37.8% a year ago as AI compute costs climbed.
• Management modestly raised full-year revenue guidance to about $680.5 million at the midpoint.
• Billings of $165.7 million grew 9.5% year over year, yet shares slipped roughly 6.7% after the report amid margin concerns.
• For more detail on Doximity's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for ongoing coverage.
• To see how AI-powered strategies are positioned across the market, explore Trending AI Robots.

Earnings Context and Why It Matters

Doximity's fiscal second quarter 2027 results, for the period ended September 30, 2026, arrived at a pivotal moment for the medical professional network. The company has been aggressively investing in artificial intelligence while navigating a softer market for digital pharmaceutical advertising, its core revenue driver. Investors were watching closely to see whether accelerating AI compute spending would pressure a historically high-margin business, and whether demand from health systems could offset weakness in pharma advertising. The report mattered because it tested Doximity's ability to preserve profitability during a strategic transition from a high-margin advertising model toward subscription-based AI tools for clinicians and health systems.

Reported Results

Doximity reported revenue of $174.5 million for its fiscal second quarter of 2027, up 3.6% year over year and ahead of the consensus estimate of roughly $171.1 million. Adjusted EPS came in at $0.36, essentially in line with the consensus of $0.35. On a non-GAAP basis (figures that exclude certain items not aligned with Generally Accepted Accounting Principles), adjusted EBITDA totaled $88.9 million, beating the consensus estimate of about $81.5 million and reflecting a 50.9% adjusted EBITDA margin.

Profitability under GAAP (Generally Accepted Accounting Principles) told a more pressured story: operating margin narrowed to 25.2%, down sharply from 37.8% in the year-ago quarter, driven by higher AI compute costs. Free cash flow margin improved to 52.3% from 25.3% in the prior quarter. Billings, a forward-looking measure of invoiced activity, rose 9.5% year over year to $165.7 million. Management raised its full-year revenue guidance to about $680.5 million at the midpoint, while issuing full-year EBITDA guidance of approximately $321 million at the midpoint. CEO Jeff Tangney highlighted record engagement and noted that more than 190 health systems have adopted the company's AI suite.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following earnings-driven moves like Doximity's, it offers a structured way to surface comparable opportunities across the healthcare technology sector. Consider exploring the AI Screener to build a more targeted watchlist.

Market Reaction and Investor Sentiment

The market's response to Doximity's report was notably cautious. Despite a top-line beat and in-line adjusted EPS, shares fell roughly 6.7% to about $31.01 immediately after the release. The decline reflected investor unease over the meaningful compression in GAAP operating margin and the softer near-term demand in digital pharma advertising. The divergence between solid adjusted profitability and rising AI compute costs suggests the market is focused on the sustainability of Doximity's margin profile as AI usage ramps up. Sentiment heading into and following the print remained guarded, with investors weighing the company's long-term AI opportunity against the near-term cost of funding that expansion.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will likely focus on whether Doximity can balance its AI investment cycle with margin discipline. Management's raised revenue guidance signals confidence in demand, but the primary question is whether AI compute costs will continue to outpace revenue growth and further compress operating margins.

Several factors are worth monitoring. First, the trajectory of billings growth will offer a read on future subscription revenue, particularly as more health systems adopt the AI suite and products such as UpToDate and DoseCheck. Second, the state of the digital pharma advertising market remains a swing factor, given management's previously noted softness and limited visibility in that segment.

Finally, watch for updates on customer retention and the net revenue retention rate, as well as how share repurchases interact with the higher stock-based compensation expected in fiscal 2027. These elements will help determine whether the company's profitability can stabilize even as it prioritizes long-term AI expansion.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations